Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
363 studies found for:    Open Studies | "heart disease"OR"stroke"OR"cardiovascular disease" | United States | Phase 1, 2, 3, 0 | Industry
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "heart disease"OR"stroke"OR"cardiovascular disease" | United States | Phase 1, 2, 3, 0 | Industry
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Patients With Hyperlipoproteinemia(a) and Cardiovascular Disease
Conditions: Elevated Lipoprotein(a);   Cardiovascular Disease
Interventions: Drug: ISIS 681257;   Drug: Placebo
2 Recruiting BIONICS - Pharmacokinetics (PK) Trial
Condition: Heart Disease
Intervention: Device: BioNIR Ridaforolimus Eluting Coronary Stent
3 Recruiting Evaluation of Safety and Efficacy of Lumason in Pediatric Echocardiography
Condition: Congenital Heart Disease
Intervention: Drug: sulphur hexafluoride lipid-type A microspheres
4 Recruiting Ranolazine Mediated PVC Reduction in Ischemic Heart Disease
Conditions: Ventricular Premature Complexes;   Myocardial Ischemia
Intervention: Drug: ranolazine
5 Recruiting Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation
Conditions: Transient Ischemic Attack;   Stroke;   Atrial Fibrillation
Interventions: Drug: Apixaban;   Drug: Warfarin
6 Recruiting Multiple Ascending Doses of MEDI6012 in Subjects With Stable Atherosclerotic Cardiovascular Disease
Conditions: Atherosclerosis;   Cardiovascular Disease
Interventions: Biological: MEDI6012;   Biological: Placebo
7 Recruiting Evaluation of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo
Conditions: Cardiovascular Diseases;   Statin Adverse Reaction
Interventions: Drug: Bempedoic acid 180 mg tablet;   Drug: Matching placebo tablet
8 Recruiting Active Preoperative Anemia Management in Patients Undergoing Cardiac Surgery
Conditions: Anemia;   Cardiovascular Disease
Interventions: Drug: EPO;   Drug: Feraheme
9 Recruiting Targeted Electrotherapy for Aphasia Stroke Rehabilitation (TEASER) - Phase II Multi-Center Study
Condition: Chronic Aphasia
Interventions: Device: HD-tDCS (Soterix Medical, Active);   Device: HD-tDCS (Soterix Medical, Sham)
10 Recruiting Use of Lexiscan for Myocardial Stress Perfusion Computed Tomography With a 3rd Generation Dual Source CT System
Conditions: Cardiovascular Diseases;   Coronary Artery Disease
Intervention: Drug: Lexiscan
11 Not yet recruiting Diffuse Optical Monitoring With Inhaled Nitric Oxide
Condition: Stroke
Intervention: Drug: Nitric Oxide
12 Recruiting Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk
Conditions: Hypercholesterolemia;   Atherosclerotic Cardiovascular Disease
Interventions: Drug: bempedoic acid;   Drug: placebo
13 Recruiting Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant
Conditions: Hypercholesterolemia;   Atherosclerotic Cardiovascular Disease;   Statin Adverse Reaction
Interventions: Drug: bempedoic acid;   Other: placebo
14 Not yet recruiting ASIS for Botox in Upper Limb Spasticity
Conditions: Upper Limb Spasticity Unilaterally in Adults With History of Stroke;   Increased Muscle Tone in Elbow, Wrist, Finger, and Thumb Flexors.
Interventions: Drug: Gadolinium;   Drug: Efficacy of Botox intramuscularly at Week 6;   Drug: Efficacy of Botox intramuscularly at Week 12,;   Drug: Efficacy of Botox intramuscularly at Week 18;   Drug: Efficacy of Botox intramuscularly at Week 24;   Drug: Efficacy of Botox intramuscularly at Week 30;   Drug: Efficacy of Botox subdermally at Week 6;   Drug: Efficacy of Botox subdermally at Week 12;   Drug: Efficacy of Botox subdermally at Week 18;   Drug: Efficacy of Botox subdermally at Week 24;   Drug: Efficacy of Botox subdermally at Week 30;   Drug: Adverse Reactions of Botox intramuscularly;   Drug: Adverse Reactions of Botox subdermally
15 Recruiting The Medtronic Harmony™ Transcatheter Pulmonary Valve Clinical Study
Conditions: Congenital Heart Disease;   Tetrology of Fallot;   RVOT Anomaly;   Pulmonary Regurgitation
Interventions: Device: Harmony Transcatheter Pulmonary Valve;   Device: Harmony Delivery System
16 Recruiting Study of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke
Condition: Chronic Ischemic Stroke
Interventions: Biological: SB623 Implant (2.5M);   Biological: SB623 Implant (5.0M);   Procedure: Sham surgery
17 Recruiting Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study
Condition: Heart Failure
Interventions: Device: Jarvik 2000 VAS;   Device: HeartMate II
18 Recruiting Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)
Condition: Stroke
Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Aspirin (Acetylsalicylic acid, BAY1019036);   Other: Rivaroxaban-Placebo;   Other: Aspirin-Placebo
19 Recruiting Study With Healthy Japanese and Non-Asian Participants With BMS-986231
Condition: Heart Decompensation, Acute
Interventions: Drug: BMS-986231;   Drug: BMS-986231 Placebo
20 Recruiting Sub-Q Versus IV Furosemide in Acute Heart Failure
Condition: Congestive Heart Failure
Interventions: Drug: Furosemide Injection Solution (SCP-101);   Drug: Furosemide Injection Solution, USP

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.